Pros: Former Alphabet company; used to share perks with Google.

Cons: Frequent changes in senior leadership have led to shifts in business priorities, resulting in a direction that differs from the company’s original focus when I joined.

Pros: Excellent Teammates (smart + helpful). Great Compensation + benefits.

Cons: Product Roadmap: Good, not Great. Company spread too thin (management issue). Could have better transparency between upper and lower management.

Pros: Some individual contributors are still trying to do good work despite circumstances. Office locations are decent.

Cons: This company is in a death spiral. Employees watched their equity crater 80% in value (September 2025 reports), while leadership spins it as "strategic repositioning." The benefits that once attracted talent have eroded; competitive compensation is a distant memory. The "Google DNA" has left the building either voluntarily or via layoffs, and those that haven't yet been able to find other roles are beginning to become tainted in the eyes of recruiters in my network. Current products are me-too offerings entering saturated markets years late, burdened by technical debt and built by teams whose morale has been systematically destroyed. Leadership infighting is visible at every level. The ongoing HIPAA violation lawsuit, alleging cover-ups affecting 25,000+ patients, should terrify any pharma partner – this company can't execute on products and poses compliance risks. The August 2025 device division shutdown, after years of investment, shows the pattern: pivot, burn cash, fail, pivot again. Now pivoting to "AI and precision health" – the same vague promises, just following different buzzwords. The LLC-to-C-corp restructuring could signal desperation for any funding at any terms, or preparation for asset sales and wind-down. The innovative, mission-driven culture that once existed has been replaced by bureaucratic paralysis, risk aversion, and executives who seem contemptuous of their own workforce. Decision-making is glacial, initiatives die in endless approval loops, and the few remaining optimists seem detached from reality.